Janux Therapeutics (JANX)
(Real Time Quote from BATS)
$43.30 USD
+0.08 (0.19%)
Updated Jun 25, 2024 09:58 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Janux Therapeutics, Inc. [JANX]
Reports for Purchase
Showing records 1 - 20 ( 33 total )
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Data Updates on TRACTr Clinical Programs; New $63 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TRACTr Clinical Programs on Track; New $50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Data Updates Underscore TRACTr Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for JANX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JANX-007 and JANX-008 Studies Remain on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TRACTr Gained Validation; JANX-007 and JANX-008 Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Look at ?007: Early Proof of Potent Profile and Platform
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Clinical Data Validates JANX007 Potential as T Cell Engager; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Two Clinical Programs on Track With Third to Initiate in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S